Ovid Therapeutics Overview
- Founded
-
2014
- Status
-
Public
- Employees
-
44
- Stock Symbol
-
OVID
- Investments
-
1
- Share Price
-
$2.42
- (As of Wednesday Closing)
Ovid Therapeutics General Information
Description
Ovid Therapeutics Inc is a biopharmaceutical company. The firm is primarily engaged in developing impactful medicines for patients and families living who are suffering from epilepsies, seizure-related disorders, and neurological disorders. It is targeting disorders such as intellectual disability, severe speech impairment, problems with movement and balance, sleep disorders and anxiety to transform the patient's life.
Contact Information
Primary Industry
Drug Discovery
Stock Exchange
NAS
Primary Office
- 1460 Broadway
- Suite 15021
- New York, NY 10036
- United States
+1 (646) 000-0000
Ovid Therapeutics Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.42 | $2.50 | $1.41 - $3.55 | $176M | 70.5M | 88K | -$0.99 |
Ovid Therapeutics Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | (6,827) | 16,796 | 59,669 | 160,530 |
| Revenue | 1,456 | 208,383 | 12,617 | 0 |
| EBITDA | (68,015) | 124,400 | (80,729) | (60,206) |
| Net Income | (68,664) | 122,835 | (81,036) | (60,461) |
| Total Assets | 165,032 | 194,545 | 75,926 | 80,844 |
| Total Debt | 16,249 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Ovid Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Ovid Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Ovid Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Ovid Therapeutics Inc is a biopharmaceutical company. The firm is primarily engaged in developing impactful medicines fo
Drug Discovery
New York, NY
44
As of 2022
00000
000000000
00000
000000
amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore e
0000 000000000
San Carlos, CA
00
As of 0000
000.00
000
0000-00-00
00000000000
000.00
000000
et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullam
0000 000000000
New York, NY
00
As of 0000
000.00
00000000
000.00
Add Comparison
Ovid Therapeutics Competitors (14)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CuraSen | Venture Capital-Backed | San Carlos, CA | 00 | 000.00 | 00000000000 | 000.00 |
| 000000000 00000000 | Formerly VC-backed | New York, NY | 00 | 000.00 | 00000000 | 000.00 |
| 000000000000 | Venture Capital-Backed | Clarksville, MD | 0 | 00.000 | 00000000000 | |
| 0000000 0000000000 | Venture Capital-Backed | South San Francisco, CA | 00 | 00000 | 00000000000 | 00000 |
| 00000000 000000000 | Corporation | Coral Gables, FL | 00 | 000.00 | 00000000 | 000.00 |
Ovid Therapeutics Patents
Ovid Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2020405060-A1 | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome | Pending | 18-Dec-2019 | 0000000000 | |
| CA-3164635-A1 | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome | Pending | 18-Dec-2019 | 0000000000 | |
| EP-4051272-A1 | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome | Pending | 18-Dec-2019 | 0000000000 | |
| EP-4051272-A4 | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome | Pending | 18-Dec-2019 | 0000000000 | |
| US-11364228-B2 | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome | Active | 18-Dec-2019 | A61K31/437 | 00 |
Ovid Therapeutics Executive Team (15)
Ovid Therapeutics Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Barbara Duncan | Ovid Therapeutics | Board Member | 000 0000 |
| Bart Friedman JD | Self | Board Member | 000 0000 |
| Jeremy Levin Ph.D | Ovid Therapeutics | Chief Executive Officer & Chairman | 000 0000 |
| Karen Bernstein Ph.D | Self | Board Member | 000 0000 |
| Kevin Fitzgerald | Ovid Therapeutics | Board Member | 000 0000 |
Ovid Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Ovid Therapeutics Investments (1)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 | 06-Sep-2022 | 00000 0000 | 000 | Biotechnology | 000000 00 |
Ovid Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 12, 2019
29.96 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 14,042
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 947
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 427
Rank
00.00
Percentile
